Budde LE, Assouline S, Sehn LH, Schuster SJ, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol 2022;40:481-491.
PMID: 34914545